Korea Bio-Gen Co.Ltd (318000) — Financial Flexibility Index
Korea Bio-Gen Co.Ltd (318000) has a Financial Flexibility Index of 0.03x as of March 2026. Free cash flow of ₩187.92 Million (operating CF ₩145.77 Million minus capex ₩42.14 Million) represents 0% of total liabilities (₩6.68 Billion). Check strategic asset allocation of Korea Bio-Gen Co.Ltd to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Korea Bio-Gen Co.Ltd Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for Korea Bio-Gen Co.Ltd across 9 annual periods. See Korea Bio-Gen Co.Ltd (318000) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Korea Bio-Gen Co.Ltd (2017–2025)
Year-by-year free cash flow to debt coverage for Korea Bio-Gen Co.Ltd. For the full company profile including market capitalisation, see Korea Bio-Gen Co.Ltd stock valuation.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.44x | ₩7.80 Billion | ₩7.34 Billion | ₩5.42 Billion | ▲ +2.9% |
| 2024 | 1.40x | ₩9.41 Billion | ₩4.29 Billion | ₩6.73 Billion | ▼ -54.2% |
| 2023 | 3.05x | ₩11.89 Billion | ₩9.47 Billion | ₩3.90 Billion | ▲ +526.6% |
| 2022 | 0.49x | ₩3.96 Billion | ₩1.67 Billion | ₩8.13 Billion | ▼ -7.3% |
| 2021 | 0.52x | ₩5.45 Billion | ₩3.09 Billion | ₩10.39 Billion | ▼ -55.8% |
| 2020 | 1.19x | ₩3.45 Billion | ₩2.58 Billion | ₩2.91 Billion | ▼ -47.5% |
| 2019 | 2.26x | ₩5.60 Billion | ₩3.05 Billion | ₩2.47 Billion | ▲ +607.6% |
| 2018 | 0.32x | ₩2.83 Billion | ₩1.98 Billion | ₩8.83 Billion | ▲ +16.6% |
| 2017 | 0.27x | ₩2.16 Billion | ₩1.38 Billion | ₩7.88 Billion | — |